SCF ENCYCLOPEDIA ENTRY

RETAINED PRODUCTS OF CONCEPTION (RPOC)

SCF-RDOS Registry Code: SCF-RDOS-PPD-HM-004

Disease Type Classification: Obstetric Recovery Disorder → Placental Tissue Retention Syndrome → Postpartum Hemorrhagic and Endometrial Dysfunction Disease

Adaptive Module Activation:

• Universal Core Module
• Obstetric Recovery Expansion
• Hematologic Disease Expansion
• Endometrial Regeneration Expansion
• Vascular Remodeling Expansion
• Inflammatory Disease Expansion
• Reproductive Tissue Repair Expansion

1. SCOPE & POSITIONING

Etiology / Classification

Retained Products of Conception (RPOC) refers to the persistence of placental tissue, fetal membranes, trophoblastic tissue, or other gestational remnants within the uterine cavity following childbirth, miscarriage, termination of pregnancy, or cesarean delivery.

Normally, complete placental separation and expulsion occur during the third stage of labor, followed by rapid uterine involution and vascular closure. When tissue remains within the uterine cavity, persistent biologic activity interferes with normal postpartum recovery.

Within the SCF framework, RPOC is classified as:

A postpartum endometrial-regenerative failure syndrome characterized by persistence of gestational tissue resulting in ongoing angiogenic signaling, impaired uterine involution, chronic inflammatory activation, abnormal vascular remodeling, and secondary hemorrhagic instability.

SCF Classification

SCF Disease Category: Postpartum Tissue Clearance Failure Syndrome

SCF Functional Class:

Maternal Endometrial-Placental Resolution Dysfunction Disorder

SCF Fault Tier Classification

Clinical Significance

Retained Products of Conception represent one of the most common causes of Secondary Postpartum Hemorrhage and postpartum readmission.

Potential complications include:

• Secondary postpartum hemorrhage
• Persistent vaginal bleeding
• Endometritis
• Uterine infection
• Sepsis
• Chronic pelvic pain
• Intrauterine adhesions
• Subfertility
• Infertility
• Recurrent pregnancy complications

SCF Domain Alignment

Primary Domains:

• Reproductive
• Endometrial
• Vascular
• Hematologic

Secondary Domains:

• Immune
• Inflammatory
• Endocrine
• Regenerative

2. ETIOPATHOGENIC CORE

Primary Cause

RPOC develops when complete placental and gestational tissue evacuation fails, allowing biologically active tissue to persist within the uterine cavity.

This retained tissue continues to produce:

• Angiogenic factors
• Inflammatory mediators
• Trophoblastic signals
• Vascular maintenance signals

Resulting in disruption of normal postpartum involution.

Key Drivers

Driver A — Incomplete Placental Separation

Risk factors include:

• Placenta accreta spectrum
• Abnormal placentation
• Prolonged third stage of labor
• Manual placental extraction

Result:

• Residual placental fragments

Driver B — Persistent Angiogenic Signaling

Retained trophoblastic tissue continues producing:

• VEGF
• Placental growth factors
• Angiogenic mediators

Result:

• Ongoing uterine vascularization

Driver C — Endometrial Healing Failure

Persistent tissue prevents:

• Endometrial remodeling
• Normal involution
• Tissue regeneration

Result:

• Delayed recovery

Driver D — Chronic Inflammatory Activation

Retained tissue acts as:

• Inflammatory stimulus
• Foreign biologic substrate

Result:

• Endometrial inflammation

Driver E — Secondary Infection

Retained tissue may serve as:

• Bacterial growth substrate
• Persistent inflammatory focus

Result:

• Endometritis and sepsis risk

3. SCF FAULT ARCHITECTURE

4. PATHOGENESIS FLOW (SCF LOGIC)

Delivery

↓

Placental Separation

↓

Incomplete Tissue Expulsion

↓

Residual Gestational Tissue

↓

Persistent Trophoblastic Activity

↓

Continued Angiogenic Signaling

↓

Failure of Placental-Bed Remodeling

↓

Delayed Endometrial Recovery

↓

Persistent Uterine Vascularity

↓

Secondary Hemorrhage

Inflammation

↓

Endometritis

↓

Chronic Uterine Dysfunction

5. CLINICAL SPECTRUM

6. SCF TRINITY FRAMEWORK MAPPING

Trinity Axis I — Structural Integrity

Affected Systems:

• Endometrium
• Placental implantation site
• Myometrium
• Uterine cavity

Primary Failure:

• Incomplete tissue resolution

Trinity Axis II — Energetic Integrity

Affected Systems:

• Regenerative pathways
• Cellular repair mechanisms
• Endometrial recovery systems

Primary Failure:

• Regenerative arrest

Trinity Axis III — Informational Integrity

Affected Systems:

• Placental signaling pathways
• Angiogenic regulation networks
• Endometrial repair signaling

Primary Failure:

• Persistence of pregnancy-associated biologic signaling

7. RETAINED TISSUE EXPANSION MODULE

Clinical Subtype Registry

Type A

Placental Fragment Retention Syndrome

Characteristics:

• Residual placental tissue
• Most common subtype

Type B

Membranous Retention Syndrome

Characteristics:

• Retained fetal membranes
• Persistent discharge

Type C

Trophoblastic Persistence Syndrome

Characteristics:

• Active trophoblastic tissue
• Elevated biologic activity

Type D

Hemorrhagic RPOC Syndrome

Characteristics:

• Secondary postpartum hemorrhage
• Hypervascular lesions

Type E

Infected RPOC Syndrome

Characteristics:

• Endometritis
• Sepsis risk

8. MULTI-OMICS PATHOGENESIS MAP

9. SCF PCR THERAPEUTIC STRATEGY

PREVENTATIVE

Objectives

Prevent tissue retention following delivery.

Targets:

• Placental completeness
• Third-stage labor management
• Placental-bed inspection
• High-risk placentation identification

CURATIVE

Objectives

Remove retained tissue and restore uterine recovery.

Targets:

• Persistent gestational tissue
• Angiogenic activity
• Hemorrhage
• Infection

Interventions:

• Uterine evacuation
• Hysteroscopic removal
• Antibiotic therapy when indicated
• Hemorrhage control measures

RESTORATIVE

Objectives

Restore normal endometrial architecture and fertility potential.

Targets:

• Endometrial regeneration
• Uterine involution
• Vascular normalization
• Reproductive tissue recovery

Potential strategies:

• Endometrial regenerative platforms
• Precision uterine repair systems
• SCF-derived tissue-resolution therapeutics
• Fertility-preservation recovery programs

10. CURRENT STANDARD OF CARE

Diagnostic Evaluation

Clinical Assessment

• Persistent postpartum bleeding
• Pelvic pain
• Fever
• Abnormal lochia

Laboratory Evaluation

• Complete blood count
• β-hCG when indicated
• Inflammatory markers
• Blood cultures if sepsis suspected

Imaging

Primary:

• Transvaginal ultrasound

Advanced:

• Color Doppler ultrasonography
• MRI when diagnosis remains uncertain

Treatment

Medical Management

Selected cases:

• Uterotonic therapy
• Antibiotic therapy
• Observation for small avascular remnants

Procedural Management

• Vacuum aspiration
• Dilation and curettage
• Hysteroscopic resection

Advanced Intervention

• Uterine artery embolization
• Surgical management of invasive placentation
• Hysterectomy in life-threatening cases

11. SCF THERAPEUTIC ENGINEERING OPPORTUNITIES

SCF Target Cluster A

Tissue Resolution Platform

Targets:

• Residual trophoblastic activity
• Placental tissue persistence
• Biologic clearance mechanisms

SCF Target Cluster B

Endometrial Regeneration Platform

Targets:

• Endometrial stem cell activation
• Tissue repair pathways
• Regenerative signaling

SCF Target Cluster C

Angiogenic Normalization Platform

Targets:

• VEGF regulation
• Placental-bed vascular remodeling
• Endothelial stabilization

SCF Target Cluster D

Fertility Preservation Platform

Targets:

• Adhesion prevention
• Uterine cavity restoration
• Reproductive function recovery

12. TRANSLATIONAL BLUEPRINT

Diagnostic Biomarkers

Tissue Persistence

• β-hCG
• Placental protein biomarkers

Angiogenic

• VEGF
• Placental Growth Factor (PlGF)

Inflammatory

• CRP
• IL-6
• Procalcitonin

Regenerative

• Endometrial remodeling biomarkers
• Matrix remodeling markers

Clinical Endpoints

Primary:

• Complete elimination of retained tissue

Secondary:

• Resolution of bleeding
• Resolution of infection
• Restoration of uterine involution
• Preservation of fertility

FDA Translational Pathway

Preclinical

↓

IND

↓

Phase I Safety

↓

Phase II Proof-of-Concept

↓

Phase III Clinical Outcomes

↓

NDA/BLA Submission

13. SCF DBI INTERPRETATION

Decentralized Biological Intelligence Failure

Cellular Layer

Trophoblastic and endometrial cells fail to execute programmed postpartum resolution.

Tissue Layer

The placental implantation site remains biologically active beyond its intended physiologic lifespan.

Organ Layer

The uterus cannot complete normal involution and regeneration because gestational signaling persists.

System Layer

Hemostatic, regenerative, angiogenic, and immune recovery systems become chronically desynchronized.

Whole-Organism Layer

Maternal postpartum recovery is disrupted by continued pregnancy-associated tissue activity within a system that should have transitioned fully to the non-pregnant state.

14. SCF LAYMAN’S SUMMARY

Retained Products of Conception occur when pieces of placenta, fetal membranes, or other pregnancy-related tissues remain inside the uterus after childbirth.

According to the SCF model, these retained tissues continue sending biologic signals that keep blood vessels active and prevent the uterus from fully healing. This can cause prolonged bleeding, infection, pelvic pain, and delayed postpartum recovery.

Common symptoms include:

• Persistent vaginal bleeding
• Passage of tissue or clots
• Pelvic pain
• Fever
• Foul-smelling discharge
• Delayed uterine recovery

Most cases can be successfully treated when recognized early, but untreated RPOC can lead to serious hemorrhagic, infectious, and reproductive complications.

SCF-RDOS INDICATION SUMMARY